Completed PHASE4 INTERVENTIONAL 1-arm NCT01051960

Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan

Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan: A Prospective Single Center, Open Label, Pilot Study

Sponsor: Gilead Sciences

Conditions Pulmonary Hypertension Shortness of Breath Systemic Sclerosis

Interventions Ambrisentan

Updated 8 times since 2017 Last updated: Oct 28, 2020 Started: Mar 31, 2009 Primary completion: Jun 30, 2010 Completion: Jan 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Pulmonary Hypertension and Shortness of Breath, this trial is completed. The trial is conducted by Gilead Sciences and has accumulated 8 data snapshots since 2009. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Dec 2020 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — Dec 2020 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Mar 2018 — Jun 2018 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Feb 2017 — Mar 2018 [monthly]

Unknown Status PHASE4
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE4

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gilead Sciences
University of California, Los Angeles

Data source: University of California, Los Angeles

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States